Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Sena Durgun"'
Publikováno v:
STEMedicine, Vol 4, Iss 3 (2023)
Background: DE605 is a c-MET inhibitor that can be taken orally. Sorafenib is the only treatment that has been proven to increase overall survival rates in patients with advanced hepatocellular carcinoma (HCC). However, the effectiveness of sorafenib
Externí odkaz:
https://doaj.org/article/1d4bd4204d014ea89efb536400e798a2
